MMMala MainiMD, PhDSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Rationale for modulating innate immunity: TLR, RIG- and others | Mala Maini, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Antiviral effect of the RIG-I agonist, Inarigavir | Nezam AfdahlView Slideset
JFJordan FeldMD, MPHSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018What are the pros and cons of HBsAg loss as the endpoint for treatment? | Jordan Feld, MD, MPHView Slideset
AGAdam GehringPhDSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Will HBsAg depletion restore HBV specific immunity? | Adam Gehring, PhDView Slideset
TBThomas BergMDSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Stopping Nucleos(t)ide Analogues: When is it beneficial, when is it dangerous? | Thomas Berg, MDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Immune reconstitution with current available antiviral therapies: a baseline to gauge new immunotherapies | Andre BoonstraView Slideset
HJHarry JanssenMD, PhDSlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018What is the cure rate with current therapies? | Harry Janssen, MD, PhDView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Targeting HBV Core Protein to Clear Infection and Achieve Higher Cure Rates | Richard ColonnoView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Establishing functional control of HBV and HDV infection with REP 2139-based combination therapy | Andrew VaillantView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Clinical update, antiviral effect and mode of action of capsid assembly modulators | Jeysen YogaratnamView Slideset
SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Clinical update on reducing HBV virus and antigen production using RNAi | Bruce GivenView Slideset
SLStephen LocarniniBSc(Hons), PhD, MBBS, FRC(Path)SlidesetViral Hepatitis and Liver DiseaseInternational Workshop on HBV Cure 2018Rationale for different Virological Targets in HBV | Stephen Locarnini, BSc(Hons), PhD, MBBS, FRC(Path)View Slideset
